Lars Bauer

4.4k total citations · 1 hit paper
67 papers, 3.0k citations indexed

About

Lars Bauer is a scholar working on Neurology, Rheumatology and Pathology and Forensic Medicine. According to data from OpenAlex, Lars Bauer has authored 67 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Neurology, 30 papers in Rheumatology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Lars Bauer's work include Spondyloarthritis Studies and Treatments (24 papers), Parkinson's Disease Mechanisms and Treatments (23 papers) and Rheumatoid Arthritis Research and Therapies (21 papers). Lars Bauer is often cited by papers focused on Spondyloarthritis Studies and Treatments (24 papers), Parkinson's Disease Mechanisms and Treatments (23 papers) and Rheumatoid Arthritis Research and Therapies (21 papers). Lars Bauer collaborates with scholars based in Germany, United States and Netherlands. Lars Bauer's co-authors include Rupert Sandbrink, Ludwig Kappos, Frederik Barkhof, Xavier Montalbán, Gilles Edan, Mark S. Freedman, Christoph Pohl, David H. Miller, Chris H. Polman and HP Hartung and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Neurology.

In The Last Decade

Lars Bauer

64 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

2006 501 citations Ludwig Kappos, Mark S. Freedman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Bauer Germany	23	1.9k	1.4k	1.1k	497	414	67	3.0k
Hélène Zéphir France	33	2.6k 1.4×	1.7k 1.2×	954 0.9×	419 0.8×	341 0.8×	121	3.4k
Mark S. Freedman Canada	25	2.9k 1.5×	1.3k 1.0×	937 0.9×	492 1.0×	635 1.5×	44	3.5k
B. Mark Keegan United States	31	2.0k 1.1×	2.0k 1.4×	653 0.6×	267 0.5×	262 0.6×	96	3.4k
Ilya Kister United States	33	2.0k 1.1×	981 0.7×	382 0.4×	268 0.5×	346 0.8×	110	2.7k
Carlos Nos Spain	34	3.3k 1.8×	1.6k 1.1×	1.2k 1.1×	366 0.7×	751 1.8×	71	4.1k
Imke Metz Germany	31	2.2k 1.2×	1.2k 0.8×	488 0.5×	571 1.1×	536 1.3×	72	3.3k
Dejan Jakimovski United States	29	2.1k 1.1×	764 0.5×	511 0.5×	288 0.6×	310 0.7×	179	3.0k
Carmen Tur Spain	31	2.7k 1.4×	1.2k 0.9×	751 0.7×	154 0.3×	474 1.1×	109	3.6k
Lawrence Jacobs United States	28	2.3k 1.2×	1.3k 0.9×	809 0.8×	367 0.7×	505 1.2×	56	3.6k
Nicolas Collongues France	28	2.0k 1.0×	1.6k 1.2×	523 0.5×	265 0.5×	290 0.7×	105	2.7k

Countries citing papers authored by Lars Bauer

Since Specialization

Citations

This map shows the geographic impact of Lars Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Bauer more than expected).

Fields of papers citing papers by Lars Bauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Bauer. The network helps show where Lars Bauer may publish in the future.

Co-authorship network of co-authors of Lars Bauer

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Bauer. A scholar is included among the top collaborators of Lars Bauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Bauer. Lars Bauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rudwaleit, Martín, Atul Deodhar, Lars Bauer, et al.. (2024). Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status. RMD Open. 10(2). e003884–e003884.

Bauer, Lars, et al.. (2023). Disease awareness and knowledge of stroke- and atrial fibrillation risk factors in cardiovascular patients. EP Europace. 25(Supplement_1).

Heijde, Désirée van der, Lianne S. Gensler, Walter P. Maksymowych, et al.. (2022). Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. RMD Open. 8(1). e002138–e002138. 5 indexed citations

Katsifis, Gikas, Andreas Bounas, Panagiotis Georgiou, et al.. (2022). Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study. Mediterranean Journal of Rheumatology. 33(Suppl 1). 162–162. 1 indexed citations

Horst‐Bruinsma, Irene van der, Frank D. Verbraak, Timo Räth, et al.. (2020). The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open. 6(1). e001161–e001161. 22 indexed citations

Landewé, Robert, Désirée van der Heijde, Maxime Dougados, et al.. (2020). Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Annals of the Rheumatic Diseases. 79(7). 920–928. 47 indexed citations

Baraliakos, Xenofon, Torsten Witte, Luc S. De Clerck, et al.. (2020). Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. Lara D. Veeken. 60(1). 113–124. 4 indexed citations

Coates, Laura C., Joseph F. Merola, Oliver FitzGerald, et al.. (2019). AB0742 ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. Annals of the Rheumatic Diseases. 78. 1836–1837. 2 indexed citations

Heijde, Désirée van der, Xenofon Baraliakos, Kay‐Geert Hermann, et al.. (2018). Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Annals of the Rheumatic Diseases. 77(5). 699–705. 90 indexed citations

10.

Heijde, Désirée van der, Atul Deodhar, Oliver FitzGerald, et al.. (2018). 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open. 4(1). e000582–e000582. 30 indexed citations

11.

Bauer, Lars, et al.. (2018). Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson’s disease. Current Medical Research and Opinion. 34(7). 1293–1299. 3 indexed citations

12.

Müller, Thomas, Eduardo Tolosa, Mahnaz Asgharnejad, et al.. (2018). An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson’s disease. Journal of Neural Transmission. 125(6). 953–963. 14 indexed citations

13.

Giladi, Nir, Anthony P. Nicholas, Mahnaz Asgharnejad, et al.. (2016). Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage. Journal of Parkinson s Disease. 6(4). 741–749. 13 indexed citations

14.

Nicholas, Anthony P., Rupam Borgohain, Pedro Chaná, et al.. (2014). A Randomized Study of Rotigotine Dose Response on ‘Off’ Time in Advanced Parkinson's Disease. Journal of Parkinson s Disease. 4(3). 361–373. 36 indexed citations

15.

Kappos, Ludwig, Mark S. Freedman, Chris H. Polman, et al.. (2009). Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. The Lancet Neurology. 8(11). 987–997. 257 indexed citations

16.

Pohl, Christoph, Chris H. Polman, Frederik Barkhof, et al.. (2009). MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurology. 9(1). 19–19. 16 indexed citations

17.

Hartung, HP, Ludwig Kappos, C. Polman, et al.. (2007). Betaferon (R)/betaseron (R) in newly emerging multiple sclerosis for initial treatment (benefit): Effects of early vs. delayed treatment with interferon beta-1B. UCL Discovery (University College London).

18.

Bauer, Lars, et al.. (2007). A Self-Adaptive Extensible Embedded Processor. 344–350. 17 indexed citations

19.

Kappos, Ludwig, Mark S. Freedman, Chris H. Polman, et al.. (2007). Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. The Lancet. 370(9585). 389–397. 356 indexed citations

20.

Kappos, Ludwig, C.H. Polman, M. S. Freedman, et al.. (2005). Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): First results. UCL Discovery (University College London). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact